Annarita Tagliaferri

List of Publications by Year
in descending order

48 papers	1,269 citations	471509 17 h-index	361022 35 g-index
48 all docs	48 docs citations	48 times ranked	897 citing authors

#	Article	IF	Citations
1	Mortality and causes of death in Italian persons with haemophilia, 1990â€“2007. Haemophilia, 2010, 16, 437-446.	2.1	145
2	Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia, 2008, 14, 945-951.	2.1	124
3	Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. Journal of Thrombosis and Haemostasis, 2009, 7, 780-786.	3.8	122
4	Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study. Thrombosis and Haemostasis, 2015, 114, 35-45.	3.4	87
5	The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders. Blood, 2001, 98, 1836-1841.	1.4	80
6	Prophylaxis in Children with Hemophilia: Evidence-Based Achievements, Old and New Challenges. Seminars in Thrombosis and Hemostasis, 2012, 38, 79-94.	2.7	74
7	Inhibitor development and mortality in nonâ€severe hemophilia A. Journal of Thrombosis and Haemostasis, 2015, 13, 1217-1225.	3.8	65
8	Prophylaxis in people with haemophilia. Thrombosis and Haemostasis, 2009, 101, 674-681.	3.4	61
9	Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. Haemophilia, 2012, 18, 39-45.	2.1	51
10	The natural history of mild haemophilia: a 30â€year single centre experience. Haemophilia, 2012, 18, 166-174.	2.1	36
11	Awaiting evidenceâ€based recommendations on prophylaxis in adult patients. Haemophilia, 2010, 16, 955-956.	2.1	34
12	A webâ€based registry of inherited bleeding disorders in the region of Emiliaâ€Romagna: results at three and a half years. Haemophilia, 2008, 14, 343-354.	2.1	30
13	Emerging Issues on Comprehensive Hemophilia Care: Preventing, Identifying, and Monitoring Age-Related Comorbidities. Seminars in Thrombosis and Hemostasis, 2013, 39, 794-802.	2.7	29
14	Assessment of Hemophilic Arthropathy by Ultrasound: Where Do We Stand?. Seminars in Thrombosis and Hemostasis, 2016, 42, 541-549.	2.7	27
15	Pain assessment and management in haemophilia: A survey among Italian patients and specialist physicians. Haemophilia, 2018, 24, 766-773.	2.1	26
16	A webâ€based clinical record â€˜xlâ€™Emofilia^{Â®}â€™ for outpatients with haemophilia and allied disorders in the Region of Emiliaâ€Romagna: features and pilot use. Haemophilia, 2009, 15, 150-158.	2.1	25
17	Experience of secondary prophylaxis in 20 adolescent and adult Italian hemophiliacs. Thrombosis and Haemostasis, 2006, 96, 542-543.	3.4	22
18	F7 gene variants modulate protein levels in a large cohort of patients with factor VII deficiency. Thrombosis and Haemostasis, 2017, 117, 1455-1464.	3.4	22

#	Article	IF	Citations
19	Clinical Efficacy and Determinants of Response to Treatment with Desmopressin in Mild Hemophilia A. Seminars in Thrombosis and Hemostasis, 2013, 39, 732-739.	2.7	18
20	Spectrum of F8 gene mutations in haemophilia A patients from a region of Italy: identification of 23 new mutations. Haemophilia, 2010, 16, 791-800.	2.1	17
21	Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience. Blood Transfusion, 2020, 18, 374-385.	0.4	16
22	Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 <scp>AICE</scp> survey. Haemophilia, 2014, 20, e128-35.	2.1	15
23	Comorbidities in persons with haemophilia aged 60 years or more compared with ageâ€matched people from the general population. Haemophilia, 2018, 24, e6-e10.	2.1	15
24	Characterization of a novel mutation in the F8 promoter region associated with mild hemophiliaÂA and resistance to DDAVP therapy. Journal of Thrombosis and Haemostasis, 2009, 7, 1234-1235.	3.8	14
25	Blood Group O Protects against Inhibitor Development in Severe Hemophilia A Patients. Seminars in Thrombosis and Hemostasis, 2017, 43, 069-074.	2.7	12
26	Hemophilia severity score system: validation from an Italian Regional Hemophilia Reference Center. Journal of Thrombosis and Haemostasis, 2009, 7, 720-722.	3.8	11
27	Severe bleeding in a patient with factor XIII deficiency and COVIDâ€19. Haemophilia, 2021, 27, e140-e142.	2.1	8
28	Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE Study. Blood Transfusion, 2020, 18, 152-158.	0.4	8
29	Secondary prophylaxis in adolescent and adult haemophiliacs. Blood Transfusion, 2008, 6 Suppl 2, s17-20.	0.4	8
30	Costâ€effectiveness analysis of late prophylaxis vs. onâ€demand treatment for severe haemophilia A in Italy. Haemophilia, 2017, 23, 422-429.	2.1	7
31	Rate and appropriateness of polypharmacy in older patients with hemophilia compared with ageâ€matched controls. Haemophilia, 2018, 24, 726-732.	2.1	7
32	Improving assessment and management of pain in hemophilia: an Italian Delphi consensus statement. Blood Reviews, 2022, 51, 100885.	5.7	7
33	Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors. Haemophilia, 2022, 28, 55-64.	2.1	7
34	Experience of secondary prophylaxis in 20 adolescent and adult Italian hemophiliacs. Thrombosis and Haemostasis, 2006, 96, 542-3.	3.4	7
35	A Web Site to Improve Management of Patients with Inherited Bleeding Disorders in the Emergency Department: Results at 2 Years. Seminars in Thrombosis and Hemostasis, 2016, 42, 589-598.	2.7	5
36	Addressing the impact of SARSâ€CoVâ€2 infection in persons with congenital bleeding disorders: The Italian MECCOVIDâ€19 study. Haemophilia, 2021, 27, e575-e578.	2.1	5

#	Article	IF	Citations
37	Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentrates. Blood Transfusion, 2013, 11 Suppl 4, s101-9.	0.4	5
38	ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers. Seminars in Thrombosis and Hemostasis, 2021, 47, 084-089.	2.7	3
39	The effect of carriersâ€™ reproductive choices and pregnancy history on sporadic severe haemophilia: A 20â€year retrospective study through a regional registry. Haemophilia, 2022, 28, 308-315.	2.1	3
40	Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus. Journal of Clinical Medicine, 2022, 11, 801.	2.4	3
41	Immune tolerance induction with moroctocogâ€alpha (Refacto/Refacto AF) in a population of Italian haemophilia A patients with highâ€titre inhibitors: Data from REF.IT Registry. Haemophilia, 2019, 25, 1003-1010.	2.1	2
42	Safety and efficacy of nonacog alfa for the treatment of haemophilia B in children younger than 6 years of age in a routine clinical care setting: the EUREKIX registry study. Haemophilia, 2021, 27, e60-e68.	2.1	2
43	Enabling normal psychophysical development in children with hemophilia: the choice for prophylaxis. Pediatric Health, 2010, 4, 183-199.	0.3	1
44	Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia. Haemophilia, 2021, 27, e525-e529.	2.1	1
45	Source and Purity of Factor VIII Products As Risk Factors for Inhibitor Development In Previously Untreated Patients with Severe Hemophilia A. Blood, 2011, 118, 25-25.	1.4	1
46	Haemophilia at various stages of life: design of new therapeutic strategies through an interactive course--the Kogeniale project. Blood Transfusion, 2013, 11, 272-80.	0.4	1
47	Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers: a reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2012, 10, 1201-1202.	3.8	0
48	Type of Factor VIII Product as Inhibitor Risk Factor in Patients with Severe Hemophilia A and Null Mutations.. Blood, 2009, 114, 3500-3500.	1.4	0